Pill Identification & Overview
A light blue, round tablet debossed with “ALV” on the upper half and “196” on the lower half of a bisect (score line) on one face, and plain on the reverse, is Oxycodone Hydrochloride and Acetaminophen 5 mg / 325 mg. It is a generic formulation equivalent to the brand-name medication Percocet 5/325.
Characteristic – Specification
- Active Ingredients – Oxycodone Hydrochloride (5 mg) + Acetaminophen (325 mg)
- Drug Class – Opioid Agonist / Non-Opioid Analgesic Combination
- Color & Shape – Light blue, round, biconvex tablet
- Imprint / Markings – Debossed with “ALV” over “196”, separated by a bisect score line; reverse is plain
- Scoring – Bisected (scored)
- Manufacturer / Supplier – Alvogen, Inc.
- Controlled Status – Schedule II (C-II) Controlled Substance (Prescription only)
Mechanism of Action (Pharmacology)
The ALV 196 tablet combines two distinct analgesic agents with complementary central and peripheral pathways:
- Oxycodone Hydrochloride (Semisynthetic Opioid): Oxycodone is a pure opioid receptor agonist. When it binds to opioid receptors distributed across the brain, spinal cord, and gastrointestinal tract, it inhibits adenylate cyclase and hyperpolarizes neural membranes by opening inward-rectifying potassium channels and closing voltage-gated calcium channels. This suppresses presynaptic neurotransmitter release and blocks ascending nociceptive pain signals while modifying the emotional perception of pain.
- Acetaminophen (Non-Opioid Analgesic & Antipyretic): Acetaminophen (APAP) exerts analgesic and antipyretic properties primarily through central inhibition of prostaglandin synthesis (acting on central cyclooxygenase pathways, including and modulation of descending serotonergic pathways, enhancing overall pain relief without causing peripheral anti-inflammatory effects or platelet dysfunction.
Therapeutic Indications & Dosage
Clinical Indications
- Management of Moderate to Severe Acute Pain: Indicated for acute pain severe enough to require an opioid analgesic where alternative non-opioid treatments (such as NSAIDs or acetaminophen monotherapy) are ineffective, not tolerated, or insufficient (e.g., severe acute trauma, orthopedic surgery, post-operative recovery).
Dosage & Administration Guidelines
- Standard Adult Dosing:
- 1 tablet orally every 6 hours as needed for pain.
- Alternatively, 1 to 2 tablets every 4 to 6 hours may be prescribed based on the severity of pain and patient tolerance.
- Maximum Daily Thresholds:
- The maximum single dose and daily frequency are strictly capped by the acetaminophen component. Total daily acetaminophen intake must not exceed 4,000 mg (4 grams) in 24 hours from all prescription and OTC sources combined to prevent acute liver failure.
- In clinical practice, the maximum daily limit is usually capped at 8 to 12 tablets in 24 hours (or less if the patient has lower baseline hepatic reserve).
- Administration: May be taken with or without food. Taking the dose with food or a glass of milk can help minimize opioid-induced gastrointestinal upset.
Side Effects Profile
Common Adverse Reactions
- Drowsiness, sedation, and lightheadedness
- Nausea and vomiting (especially upon initial dosing)
- Constipation (due to decreased gastrointestinal motility)
- Dizziness and cognitive clouding
- Dry mouth (xerostomia)
- Pruritus (itching) or mild diaphoresis (sweating)
Serious & Life-Threatening Reactions
- Respiratory Depression: Profound slowing, shallowing, or cessation of breathing.
- Acute Hepatotoxicity: Severe liver injury or acute hepatic failure from exceeding daily acetaminophen limits.
- Severe Hypotension & Bradycardia: Significant drop in blood pressure, dizziness, and fainting (syncope).
- Severe Allergic Reactions (Anaphylaxis/Angioedema): Swelling of the face, throat, or tongue, difficulty breathing, and acute skin reactions (e.g., Stevens-Johnson Syndrome associated with acetaminophen).
- Adrenal Insufficiency: Decreased cortisol output presenting as persistent nausea, weakness, dizziness, and fatigue.
Precautions & Drug Interactions
- Avoid Other Acetaminophen Sources: Patients must verify that no other concurrent over-the-counter medications (cold/flu formulas, headache remedies, sleep aids like DayQuil, NyQuil, or Tylenol) contain acetaminophen.
- CYP3A4 and CYP2D6 Interactions:
- Oxycodone is metabolized via hepatic CYP3A4 (major) and CYP2D6 (minor) enzymes.
- CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, erythromycin) increase oxycodone plasma concentrations, elevating the risk of fatal respiratory depression.
- CYP3A4 Inducers (e.g., rifampin, carbamazepine, St. John’s Wort) decrease oxycodone efficacy or induce withdrawal.
- Serotonergic Medications: Co-administration with SSRIs, SNRIs, tricyclic antidepressants, or MAOIs increases the risk of serotonin syndrome.
- Physical Dependence & Tapering: Extended regular use inevitably induces physiologic tolerance and dependence. Discontinuation must be managed through a structured taper to avoid acute opioid withdrawal symptoms (rhinorrhea, lacrimation, severe anxiety, abdominal cramps, tremors, and diaphoresis).
Boxed Warnings & Critical Safety Information
FDA Black Box Warnings
- Addiction, Abuse, and Misuse: Oxycodone carries high risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.
- Life-Threatening Respiratory Depression: Fatal respiratory depression may occur, particularly upon initiation or dosage increases.
- Accidental Ingestion: Accidental ingestion of even one tablet, especially by children, can cause fatal opioid toxicity.
- Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Combining opioids with benzodiazepines, other sedatives, or alcohol causes additive CNS and respiratory depression, frequently leading to coma and death.
- Hepatotoxicity: Acetaminophen has been associated with acute liver failure, sometimes requiring liver transplantation or resulting in death.
- Neonatal Opioid Withdrawal Syndrome (NOWS): Chronic maternal use during pregnancy can precipitate life-threatening withdrawal in the newborn.
- Illicit Counterfeit Pill Danger: Blue-colored prescription opioid tablets (including “ALV 196” and “M 30” imprints) are heavily targeted for counterfeit manufacturing. Illicit counterfeit versions sold on non-medical markets frequently contain lethal doses of illicit fentanyl or designer synthetic opioids. Legitimate medications should only be obtained directly from licensed pharmacies.